Arbutus Biopharma (ABUS) Intangibles (2015 - 2019)

Arbutus Biopharma (ABUS) has reported Intangibles for 5 consecutive years, with $43.8 million the latest figure, recorded in Q2 2019.

• Quarterly Intangibles fell 25.25% year-over-year to $43.8 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $43.8 million (down 25.25% YoY) and the FY2018 annual result came in at $43.8 million, down 25.25% from the prior year.
• Intangibles steadied at $43.8 million in Q2 2019 per ABUS's latest filing, from $43.8 million in the prior quarter.
• Over the last five years, Intangibles for ABUS reached as high as $390.0 million in Q2 2015 and fell as low as $43.8 million in Q3 2018.
• A 5-year average of $165.6 million and a median of $99.4 million in 2016 frame the typical range for Intangibles.
• The largest YoY upside for Intangibles was 9.5% in 2016 against a maximum downside of 71.8% in 2016.
• Year by year, Intangibles stood at $352.6 million in 2015, then plunged by 71.8% to $99.4 million in 2016, then plunged by 41.03% to $58.6 million in 2017, then dropped by 25.25% to $43.8 million in 2018, then changed by 0.0% to $43.8 million in 2019.
• According to Business Quant data, Intangibles over the past three periods registered $43.8 million, $43.8 million, and $43.8 million for Q2 2019, Q1 2019, and Q4 2018 respectively.